Y-90-Pet/Ct Imaging Quantification For Dosimetry In Peptide Receptor Radionuclide Therapy: Analysis And Corrections Of The Impairing Factors

Purpose: We evaluated the possibility to assess Y-90-PET/CT imaging quantification for dosimetry in Y-90-peptide receptor radionuclide therapy. Methods: Tests were performed by Discovery 710 Elite (GE) PET/CT equipment. A body-phantom containing radioactive-coplanar-spheres was filled with Y-90 water solution to reproduce different signal-to-background-activity-ratios (S/N). We studied minimum detectable activity (MDA) concentration, contrast-to-noise ratio (CNR), and full-width-at-half-maximum (FWHM). Subsequently, three recovery coefficients (RC)-based correction approaches were evaluated: maximum-RC, resolution-RC, and isovolume-RC. The analysis of the volume segmentation thresholding method was also assessed to derive a relationship between the true volume of the targets and the threshold to be applied to the PET images. Y-90-PET/CT imaging quantification was then achieved on some patients and related with preclinical tests. Moreover, the dosimetric evaluation was obtained on the target regions. Results: CNR value was greater than 5 if the MDA was greater than 0.2MBq/mL with no background activity and 0.5-0.7MBq/mL with S/N ranging from 3 to 6. FWHM was equal to 7mm. An exponential fitting of isovolume RCs-based correction technique was adopted for activity quantification. Adaptive segmentation thresholding exponential curves were obtained and applied for target volume identification in three signal-to-background-activity-ratios. The imaging quantification study and dosimetric evaluations in clinical cases was feasible and the results were coherent with those obtained in preclinical tests. Conclusions: Y-90-PET/CT imaging quantification is possible both in phantoms and in patients. Absorbed dose evaluations in clinical applications are strongly related to targets activity concentration.